JP2020508313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508313A5 JP2020508313A5 JP2019545304A JP2019545304A JP2020508313A5 JP 2020508313 A5 JP2020508313 A5 JP 2020508313A5 JP 2019545304 A JP2019545304 A JP 2019545304A JP 2019545304 A JP2019545304 A JP 2019545304A JP 2020508313 A5 JP2020508313 A5 JP 2020508313A5
- Authority
- JP
- Japan
- Prior art keywords
- flt3
- leukemia
- item
- composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 claims description 137
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 80
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 80
- 208000032839 leukemia Diseases 0.000 claims description 59
- 210000004027 cell Anatomy 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 28
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 24
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 23
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 23
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 16
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 12
- 206010025323 Lymphomas Diseases 0.000 claims description 11
- 206010014958 Eosinophilic leukaemia Diseases 0.000 claims description 10
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 9
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 9
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 8
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 claims description 8
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 8
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 claims description 8
- 208000036676 acute undifferentiated leukemia Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 230000000366 juvenile effect Effects 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 206010058314 Dysplasia Diseases 0.000 claims description 7
- 206010066476 Haematological malignancy Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 210000000440 neutrophil Anatomy 0.000 claims description 7
- 102200039431 rs121913488 Human genes 0.000 claims description 7
- 102000003989 Aurora kinases Human genes 0.000 claims description 6
- 108090000433 Aurora kinases Proteins 0.000 claims description 6
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 230000036210 malignancy Effects 0.000 claims description 6
- 208000025113 myeloid leukemia Diseases 0.000 claims description 6
- 102220197937 rs1057519764 Human genes 0.000 claims description 6
- 102200039432 rs121909646 Human genes 0.000 claims description 6
- 102200039430 rs121913488 Human genes 0.000 claims description 6
- 102220197934 rs376588714 Human genes 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 2
- 229950010895 midostaurin Drugs 0.000 claims description 2
- 201000006894 monocytic leukemia Diseases 0.000 claims description 2
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 54
- 201000003444 follicular lymphoma Diseases 0.000 claims 6
- 108010016672 Syk Kinase Proteins 0.000 claims 2
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000003864 humus Substances 0.000 claims 2
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 claims 1
- 229950009240 crenolanib Drugs 0.000 claims 1
- 229950001845 lestaurtinib Drugs 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 description 12
- 210000005260 human cell Anatomy 0.000 description 7
- 229940124291 BTK inhibitor Drugs 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 230000002427 irreversible effect Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 2
- 229950006304 gilteritinib Drugs 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229950001626 quizartinib Drugs 0.000 description 2
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical group O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- 102200152078 rs1057520045 Human genes 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022197816A JP7431309B2 (ja) | 2017-02-21 | 2022-12-12 | 血液悪性腫瘍患者の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461584P | 2017-02-21 | 2017-02-21 | |
| US62/461,584 | 2017-02-21 | ||
| US201762578948P | 2017-10-30 | 2017-10-30 | |
| US62/578,948 | 2017-10-30 | ||
| PCT/US2018/018951 WO2018156578A1 (en) | 2017-02-21 | 2018-02-21 | Methods for treating patients with hematologic malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022197816A Division JP7431309B2 (ja) | 2017-02-21 | 2022-12-12 | 血液悪性腫瘍患者の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508313A JP2020508313A (ja) | 2020-03-19 |
| JP2020508313A5 true JP2020508313A5 (enExample) | 2021-04-08 |
| JP7227913B2 JP7227913B2 (ja) | 2023-02-22 |
Family
ID=63253344
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545304A Active JP7227913B2 (ja) | 2017-02-21 | 2018-02-21 | 血液悪性腫瘍患者の治療方法 |
| JP2022197816A Active JP7431309B2 (ja) | 2017-02-21 | 2022-12-12 | 血液悪性腫瘍患者の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022197816A Active JP7431309B2 (ja) | 2017-02-21 | 2022-12-12 | 血液悪性腫瘍患者の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180344702A1 (enExample) |
| EP (1) | EP3585778A4 (enExample) |
| JP (2) | JP7227913B2 (enExample) |
| KR (1) | KR20190128646A (enExample) |
| CN (1) | CN110621665A (enExample) |
| AU (2) | AU2018225539B2 (enExample) |
| CA (1) | CA3054196A1 (enExample) |
| IL (1) | IL268736A (enExample) |
| MX (1) | MX2019009954A (enExample) |
| TW (1) | TWI821174B (enExample) |
| WO (1) | WO2018156578A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3559038B1 (en) | 2016-12-21 | 2022-12-14 | The United States of America as represented by The Secretary Department of Health and Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| US20200171001A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| EP3991733A4 (en) | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| CN114828842A (zh) * | 2019-10-21 | 2022-07-29 | 理森制药股份公司 | 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物 |
| US20240091226A1 (en) * | 2021-01-05 | 2024-03-21 | Sumitomo Pharma Oncology, Inc. | Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor |
| CN117295737A (zh) * | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CN120857931A (zh) * | 2022-12-10 | 2025-10-28 | 艾普托斯生物科学公司 | 用于治疗患有血液学恶性病的患者的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| DK2940014T3 (en) * | 2012-12-28 | 2018-12-10 | Crystalgenomics Inc | 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| US10463658B2 (en) * | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| EP3062809B1 (en) * | 2013-10-31 | 2020-07-08 | Biokine Therapeutics Ltd. | A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation |
-
2018
- 2018-02-21 KR KR1020197027330A patent/KR20190128646A/ko not_active Ceased
- 2018-02-21 TW TW107105790A patent/TWI821174B/zh active
- 2018-02-21 MX MX2019009954A patent/MX2019009954A/es unknown
- 2018-02-21 JP JP2019545304A patent/JP7227913B2/ja active Active
- 2018-02-21 AU AU2018225539A patent/AU2018225539B2/en active Active
- 2018-02-21 EP EP18756992.6A patent/EP3585778A4/en not_active Withdrawn
- 2018-02-21 WO PCT/US2018/018951 patent/WO2018156578A1/en not_active Ceased
- 2018-02-21 CA CA3054196A patent/CA3054196A1/en not_active Withdrawn
- 2018-02-21 CN CN201880018924.0A patent/CN110621665A/zh active Pending
- 2018-02-21 US US15/901,439 patent/US20180344702A1/en not_active Abandoned
-
2019
- 2019-08-15 IL IL26873619A patent/IL268736A/en unknown
-
2022
- 2022-02-18 US US17/675,469 patent/US20230012148A1/en not_active Abandoned
- 2022-10-10 AU AU2022252696A patent/AU2022252696B2/en not_active Expired - Fee Related
- 2022-12-12 JP JP2022197816A patent/JP7431309B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kirtonia et al. | A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia | |
| Valent et al. | Midostaurin: a magic bullet that blocks mast cell expansion and activation | |
| Khemlina et al. | The biology of Hepatocellular carcinoma: implications for genomic and immune therapies | |
| Fathi et al. | The role of FLT 3 inhibitors in the treatment of FLT 3‐mutated acute myeloid leukemia | |
| Nikolaou et al. | Melanoma: new insights and new therapies | |
| Parikh et al. | Selective inhibitors of nuclear export (SINE)–a novel class of anti-cancer agents | |
| Hong et al. | Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1 | |
| JP6706255B2 (ja) | 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 | |
| Fagin | Perspective: lessons learned from molecular genetic studies of thyroid cancer—insights into pathogenesis and tumor-specific therapeutic targets | |
| Rizzo et al. | Defining the genomic landscape of head and neck cancers through next‐generation sequencing | |
| Wang et al. | New strategies in esophageal carcinoma: translational insights from signaling pathways and immune checkpoints | |
| Fathi et al. | FLT3 inhibitors: a story of the old and the new | |
| Hamilton et al. | Targeted therapy in haematological malignancies | |
| Fu et al. | Gene Mutations and Targeted Therapies of Myeloid Sarcoma: Fu et al. | |
| Sweeney et al. | Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials | |
| Stahl et al. | Management of myelofibrosis: JAK inhibition and beyond | |
| ES2738864T3 (es) | Combinaciones de inhibidores de MEK, EGFR y ERBB2 en el tratamiento del cáncer de pulmón causado por un mutante de KRAS | |
| Ojaswi et al. | Melanoma and its drug targets | |
| Pérez et al. | Pseudoporphyria induced by imatinib mesylate. | |
| Abudurexiti et al. | The mechanisms of imatinib resistance in gastrointestinal stromal tumours: theoretical basis and therapeutic aspect | |
| Pala et al. | Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma | |
| CA3100422A1 (en) | Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3 | |
| JP2025513929A5 (enExample) | ||
| JP2022509257A5 (enExample) | ||
| CN113941001B (zh) | Craf抑制剂在制备抗肿瘤的药物中的应用 |